Open access
2,090
Views
0
CrossRef citations to date
0
Altmetric
Report
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
Amelia C. McCuea Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USAView further author information
, Stephen J. Demarestb Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USAView further author information
, Karen J. Froningb Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USAView further author information
, Michael J. Hickeyb Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USAView further author information
, Stephen Antonysamyb Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USAView further author information
& Brian Kuhlmana Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USA;c Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USACorrespondence[email protected]
https://orcid.org/0000-0003-4907-9699View further author information
https://orcid.org/0000-0003-4907-9699View further author information
Article: 2373325
|
Received 09 Feb 2024, Accepted 24 Jun 2024, Published online: 04 Jul 2024
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.